• Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study

    Tuesday January 12th 2021

  • Bone Therapeutics completes recruitment and patient treatment in JTA-004 pivotal Phase III knee osteoarthritis study

    Tuesday December 22nd 2020

  • Mithra Announces Positive DSMB Safety Review and Continuation of its Phase III Clinical Program Donesta® in menopause

    Wednesday December 16th 2020

  • Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

    Thursday December 3rd 2020

  • reMYND commences first-in-human trial of ReS19-T Alzheimer’s program

    Thursday December 3rd 2020

  • Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial

    Tuesday December 1st 2020

  • Biocartis Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay Showing Very Low Failure Rates and Excellent Concordance with Reference Methods

    Tuesday November 17th 2020

  • First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial

    Tuesday November 10th 2020

  • Your news here?

  • Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study

    Tuesday October 20th 2020

  • Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients

    Friday October 16th 2020

  • Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion

    Wednesday October 14th 2020

Strategic Partners